|
|
|
By Drug Delivery Leader | How can genetic information be carried into lung tissue for the treatment of asthma and potentially other conditions? In this inaugural episode of In Combination, host Tom von Gunden combines the perspectives of two executives from LNP/mRNA (lipidoid nanoparticle / messenger RNA) formulation and delivery platform developer Ethris: CEO Carsten Rudolph and Chief Medical Officer Thomas Langenickel. The conversation illuminates the value to patients of platform approaches to inhalation-delivered treatments. |
|
|
|
| Characterizing Injection Factors And Their Impact On System Function | Poster | By Wendy D. Woodley, BS, Didier R. Morel, Ph.D., Diane E. Sutter, cCRA, et al., BD Medical - Pharmaceutical Systems | The transition of intravenous in-clinic chronic disease therapies to large volume subcutaneous injections in alternate settings has created an evolving roster of new formulations and treatment options. |
|
|
|
|
|
|
|
|
|
|
|
.png){kind=logo}
